— Preclinical data demonstrate potent antitumor activity of ETX-19477 and support advancing into clinical trials in multiple solid tumors — SAN DIEGO–(BUSINESS WIRE)–858 Therapeutics today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California. The presentation will describe the preclinical… The post 858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting appeared first on 8five8 Therapeutics .